Entera Bio (ENTX) Total Current Liabilities (2017 - 2026)
Entera Bio's (ENTX) quarterly Total Current Liabilities came in at $1.6 million in Q1 2026, down 2.9% YoY from $1.6 million in Q1 2025, and down 28.46% on a QoQ basis from $2.2 million in Q4 2025.
Entera Bio (ENTX) Total Current Liabilities (2017 - 2026) Analysis & Trends
Entera Bio (ENTX) has 10 years of Total Current Liabilities data on file, last reported at $1.6 million in Q1 2026.
- Quarterly Total Current Liabilities fell 2.9% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 2.9% YoY) and the FY2025 annual result came in at $2.2 million, up 87.33% from the prior year.
- Total Current Liabilities fell to $1.6 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $2.3 million in Q1 2022 to a low of $1.1 million in Q4 2023.
- A 5-year average of $1.6 million and a median of $1.6 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 57.58% — and 2025, when it surged 87.33%.
- Tracing ENTX's Total Current Liabilities over 5 years: stood at $1.3 million in 2022, then fell by 18.64% to $1.1 million in 2023, then climbed by 7.79% to $1.2 million in 2024, then soared by 87.33% to $2.2 million in 2025, then declined by 28.46% to $1.6 million in 2026.
- The last three Total Current Liabilities figures came in at $1.6 million (Q1 2026), $2.2 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | 2.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.10 Mn |
| Mar 31, 2026 | 1.58 Mn |
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 1.57 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.62 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.29 Mn |
| Mar 31, 2024 | 1.12 Mn |
| Dec 31, 2023 | 1.09 Mn |
| Sep 30, 2023 | 2.03 Mn |
| Jun 30, 2023 | 1.87 Mn |
| Mar 31, 2023 | 1.49 Mn |
| Dec 31, 2022 | 1.34 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.69 Mn |
| Mar 31, 2022 | 2.33 Mn |
| Dec 31, 2021 | 3.16 Mn |
| Jun 30, 2021 | 3.35 Mn |